GlassScriptPhysician profile
Lindsay E Anderson
NPI 1285060582
$2,041.20
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,219 · 2022: $822.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $334.54 | 2021 | |
| Lilly USA, LLC | $279.73 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.17 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $168.60 | 2021-2022 | |
| Novo Nordisk INC | $143.30 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.28 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $105.19 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $96.08 | 2021 | |
| Almatica Pharma LLC | $77.83 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $72.69 | 2022 | |
| Avanir Pharmaceuticals, INC. | $67.01 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $44.23 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $43.31 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.57 | 2022 | |
| Lundbeck LLC | $34.36 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $27.14 | 2022 | |
| Corium, LLC | $22.12 | 2022 | |
| Alkermes, INC. | $20.59 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.89 | 2022 | |
| Ironshore Pharmaceuticals INC. | $18.27 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $17.21 | 2022 | |
| Zimmer Biomet Holdings, INC. | $16.38 | 2022 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Amarin Pharma, INC. | $14.69 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.68 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.66 | 2021 | |
| Gilead Sciences, INC. | $13.68 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.